Insider · CIK 0001293789
Richard I Steinhart
Files at ATNM (Actinium Pharmaceuticals, Inc.), ATOS (ATOSSA THERAPEUTICS, INC.), BTAIQ (BioXcel Therapeutics, Inc.). First filing Dec 17, 2024, latest May 22, 2026.
Richard I Steinhart files SEC Form 4 as CFO and director at BTAIQ (BioXcel Therapeutics, Inc.), and also at ATNM (Actinium Pharmaceuticals, Inc.), ATOS (ATOSSA THERAPEUTICS, INC.). Since Dec 17, 2024, Richard I Steinhart has reported 0 open-market buys worth $0 and 2 open-market sells worth $7,634, the latest filed on May 22, 2026.
A track record needs three past buys with six months of prices behind them; Richard I Steinhart has 0, so none is measured yet.
The newest scored trade: sold $7,427 of BTAIQ on May 20, 2026, filed May 22, 2026, scored 7 (weak), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 1 sell worth $7,427.
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 7Weak | BioXcel Therapeutics, Inc. | $7,427 6,845 shares | -21% | - | |
| 2Weak | BioXcel Therapeutics, Inc. | $207 577 shares | -3% | - |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| May 20, 2026 | BTAIQ BioXcel Therapeutics, Inc. | 6,845 0.02% of outstanding | $7,426 | May 20, 2026 | none |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | 438 0.00% of outstanding | $154 | Dec 16, 2024 | $4,192 |
Transactions
The newest 50 of 53 rows this insider has filed.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | AGrant or award Common Stock | +62,800 | $0.00 | $0 | 63,116 | 39 d ago |
| Sep 2, 2026 | ATNM Actinium Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +94,200 | $0.00 | $0 | 94,200 | 39 d ago |
| Jun 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 26,335 | Jun 17, 2026 |
| Jun 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 212 | Jun 17, 2026 |
| May 4, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +17,500 | - | - | 33,145 | May 22, 2026 |
| May 20, 2026 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -6,845 | $1.09 | $7,427 | 26,300 | May 22, 2026 |
| May 4, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative10b5-1 | -17,500 | $0.00 | $0 | 52,500 | May 22, 2026 |
| May 12, 2026 | ATOS ATOSSA THERAPEUTICS, INC. | AGrant or award Common Stock | +10,000 | $0.00 | $0 | 10,000 | May 14, 2026 |
| May 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +9,000 | - | - | 15,645 | May 7, 2026 |
| May 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -9,000 | $0.00 | $0 | 0 | May 7, 2026 |
| Mar 14, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 6,610 | Mar 16, 2026 |
| Mar 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 6,645 | Mar 16, 2026 |
| Mar 14, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 97 | Mar 16, 2026 |
| Mar 15, 2026 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 247 | Mar 16, 2026 |
| Jan 1, 2026 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +70,000 | $0.00 | $0 | 70,282 | Jan 5, 2026 |
| Dec 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 6,542 | Dec 15, 2025 |
| Dec 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 6,577 | Dec 15, 2025 |
| Dec 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 130 | Dec 15, 2025 |
| Dec 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 282 | Dec 15, 2025 |
| Sep 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 6,474 | Sep 16, 2025 |
| Sep 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 6,509 | Sep 16, 2025 |
| Sep 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 163 | Sep 16, 2025 |
| Sep 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 317 | Sep 16, 2025 |
| Aug 1, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +9,000 | $0.00 | $0 | 9,000 | Aug 5, 2025 |
| Jul 22, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Common Stock | +4,375 | - | - | 5,816 | Jul 22, 2025 |
| Jul 22, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +625 | - | - | 6,441 | Jul 22, 2025 |
| Jul 22, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -625 | $0.00 | $0 | 0 | Jul 22, 2025 |
| Jun 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +33 | - | - | 1,406 | Jun 16, 2025 |
| Jun 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +35 | - | - | 1,441 | Jun 16, 2025 |
| Jun 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -33 | $0.00 | $0 | 196 | Jun 16, 2025 |
| Jun 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -35 | $0.00 | $0 | 352 | Jun 16, 2025 |
| May 15, 2025 | ATOS ATOSSA THERAPEUTICS, INC. | AGrant or award Stock Option (right to buy)derivative | +125,000 | $0.00 | $0 | 125,000 | May 16, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,500 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,500 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -2,500 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,333 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -8,333 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -18,351 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -72,156 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Mar 31, 2025 | ATNM Actinium Pharmaceuticals, Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -70,311 | $0.00 | $0 | 0 | Apr 2, 2025 |
| Jul 22, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Restricted Stock Unitsderivative | +625 | $0.00 | $0 | 625 | Apr 1, 2025 |
| Jul 22, 2024 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +1,875 | $0.00 | $0 | 1,875 | Apr 1, 2025 |
| Mar 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +31 | - | - | 1,339 | Mar 17, 2025 |
| Mar 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock | +34 | - | - | 1,373 | Mar 17, 2025 |
| Mar 14, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -31 | $0.00 | $0 | 229 | Mar 17, 2025 |
| Mar 15, 2025 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Restricted Stock Unitsderivative | -34 | $0.00 | $0 | 387 | Mar 17, 2025 |
| Jan 7, 2025 | BTAIQ BioXcel Therapeutics, Inc. | AGrant or award Stock Option (right to buy)derivative | +270,000 | $0.00 | $0 | 270,000 | Jan 10, 2025 |
| Dec 14, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +521 | - | - | 20,800 | Dec 17, 2024 |
| Dec 15, 2024 | BTAIQ BioXcel Therapeutics, Inc. | MOption exercise Common Stock10b5-1 | +562 | - | - | 21,362 | Dec 17, 2024 |
| Dec 16, 2024 | BTAIQ BioXcel Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -205 | $0.36 | $74 | 21,157 | Dec 17, 2024 |
Questions about Richard I Steinhart
Answered from the filings on this page, as of the latest one.
Is Richard I Steinhart buying or selling?
In the last 12 months Richard I Steinhart reported 0 open-market buys worth $0 and 1 open-market sell worth $7,427 on SEC Form 4; the latest was sold $7,427 of BTAIQ on May 20, 2026. Grants, option exercises and tax withholding are not counted.
How did Richard I Steinhart's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Richard I Steinhart has 0.
Where does Richard I Steinhart file Form 4?
Richard I Steinhart has filed Form 4 at BTAIQ (BioXcel Therapeutics, Inc.) as Chief Financial Officer; ATNM (Actinium Pharmaceuticals, Inc.); ATOS (ATOSSA THERAPEUTICS, INC.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.